Farmácia/Notícias da Indústria

Resumo de diretriz | Rastreamento de efeitos tóxicos na retina de pacientes em uso de antimaláricos.

2 Ago, 2021 | 18:46h

A Multidisciplinary Collaborative Approach to Retinal Toxic Effects Screening for Dermatology Patients Taking Antimalarials – JAMA Dermatology (gratuito por tempo limitado)

Diretriz original: Joint Statement: Hydroxychloroquine use with respect to retinal toxicity

---

Diretriz rápida NICE COVID-19 | Trombocitopenia trombótica imune induzida por vacina.

2 Ago, 2021 | 18:37h

COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis – National Institute for Health and Care Excellence

Comunicado de imprensa: NICE publishes new rapid guideline to diagnose and treat rare blood clotting condition associated with COVID-19 vaccination – National Institute for Health and Care Excellence

Conteúdo relacionado: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

---

Trombocitopenia trombótica imune induzida por vacina: o que se sabe e o que não se sabe.

2 Ago, 2021 | 18:33h

Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know – Blood

Conteúdo relacionado: Very rare cases of thrombosis with thrombocytopenia syndrome (TTS) after AstraZeneca vaccine: a global safety database analysis – the estimated rate of TTS after the first dose was 8.1 per million vaccinees; after the second dose, the estimated rate was 2.3 per million vaccinees. (vários artigos e fontes sobre o tema)

---

Israel irá aplicar a 3ª dose de reforço da vacina contra COVID em idosos.

2 Ago, 2021 | 18:18h

Israel to offer 3rd COVID booster shot to older citizens – Associated Press

---

Diretriz atualizada da ASCO | Tratamento endocrinológico e terapia-alvo para câncer de mama metastático positivo para receptor hormonal e negativo para receptor do fator de crescimento epidermal humano 2.

2 Ago, 2021 | 18:11h

Endocrine Treatment and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: ASCO Guideline Update – Journal of Clinical Oncology

---

Estudo randomizado | Duração da terapia adjuvante com inibidor de aromatase no câncer de mama pós-menopausa.

2 Ago, 2021 | 18:05h

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer – New England Journal of Medicine

 

Comentário no Twitter

In postmenopausal women with hormone-receptor-positive breast cancer who had 5 yrs of AI, extending adjuvant endocrine therapy by 5 years provides no benefit over a 2-year extension but is associated with a greater risk of bone fracturehttps://t.co/YDxeQVu8B9

— K Pavithran (@drkpavithran) July 29, 2021

 

---

Estudo randomizado | Em gestantes com infecção primária por citomegalovírus (CMV) diagnosticada antes de 24 semanas de gestação, a infusão de globulina hiperimune de CMV não previne a infecção congênita.

2 Ago, 2021 | 18:03h

A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus Infection – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Hyperimmune Globulin Fails to Prevent Congenital CMV – Physician’s Weekly

---

Revisão sistemática | Não há evidências que suportem o uso de ivermectina no tratamento ou na prevenção de COVID-19.

2 Ago, 2021 | 17:48h

Ivermectin for preventing and treating COVID‐19 – Cochrane Library

Resumo: Ivermectin for preventing and treating COVID-19 – Cochrane Library

Comentário: Ivermectin treatment in humans for COVID-19 – Liverpool School of Tropical Medicine

Conteúdos relacionados:

Why was a major study on ivermectin for covid-19 just retracted?

RCT: Ivermectin does not prevent hospitalizations in patients with COVID-19.

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials

RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19

---

Estudo randomizado PRINCIPLE | Doxiciclina não melhora os desfechos de pacientes ambulatoriais com suspeita de COVID-19.

2 Ago, 2021 | 17:44h

Doxycycline for community treatment of suspected COVID-19 in people at high risk of adverse outcomes in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial – The Lancet Respiratory Medicine

Comentário: PRINCIPLE: a community-based COVID-19 platform trial – The Lancet Respiratory Medicine

 

Comentário no Twitter

NEW Research—In suspected #COVID19 in the community, doxycycline was not associated with clinically meaningful reductions in time to recovery or hospital admissions or deaths, and should not be used as a routine treatment

Read the PRINCIPLE trial here https://t.co/Osw1hZLCaY pic.twitter.com/Q3VrpAO9cm

— The Lancet Respiratory Medicine (@LancetRespirMed) July 28, 2021

 

---

“Breakthrough infections” (infecções em indivíduos já vacinados) por Covid-19 em trabalhadores da área da saúde.

2 Ago, 2021 | 17:39h

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers – New England Journal of Medicine

 

Comentário no Twitter (fio – clique para saber mais)

Very important @NEJM paper today on breakthrough infections (BTI) post-vaccination in Israeli health care workers.
5 key points:
1. Of ~1500 people, 0.4% had BIs, sequenced to be Alpha 85% (this was pre-Delta)https://t.co/l69DK5Cbv4 pic.twitter.com/zDSq5e0baN

— Eric Topol (@EricTopol) July 28, 2021

 

---